US2018250247A1PendingUtilityA1
N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
Est. expiryMay 30, 2034(~7.8 yrs left)· nominal 20-yr term from priority
A61K 31/166A61K 31/198A61K 31/4745A61K 31/165A61K 31/13A61K 31/428A61P 25/28A61K 45/06Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
According to the invention there is provided N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, for use in the therapeutic treatment of a neurodegenerative disorder, such as Alzheimer's disease, Parkinson's disease, Huntington's disease and/or amyotrophic lateral sclerosis.
Claims
exact text as granted — not AI-modified1 . A method of treatment of a neurodegenerative disorder, which method comprises the administration of N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, to a patient in need of such treatment.
2 . A method of relieving one or more symptom of a neurodegenerative disorder in a patient suffering therefrom, which method comprise administering N,N-bis-2-mercaptoethyl isophthalamide, or a pharmaceutically acceptable salt or derivative thereof, to such a patient.
3 .- 10 . (canceled)Join the waitlist — get patent alerts
Track US2018250247A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.